Nanomedicine Approaches for Corneal Diseases

Overview

Journal J Funct Biomater

Specialty Biomedical Engineering

Date 2015 May 6

PMID 25941990

Citations 34

Authors

Shyam S Chaurasia

Rayne R Lim

Rajamani Lakshminarayanan

Rajiv R Mohan

Affiliations

Soon will be listed here.

Abstract

Corneal diseases are the third leading cause of blindness globally. Topical nonsteroidal anti-inflammatory drugs (NSAIDs), steroids, antibiotics and tissue transplantation are currently used to treat corneal pathological conditions. However, barrier properties of the ocular surface necessitate high concentration of the drugs applied in the eye repeatedly. This often results in poor efficacy and several side-effects. Nanoparticle-based molecular medicine seeks to overcome these limitations by enhancing the permeability and pharmacological properties of the drugs. The promise of nanomedicine approaches for treating corneal defects and restoring vision without side effects in preclinical animal studies has been demonstrated. Numerous polymeric, metallic and hybrid nanoparticles capable of transporting genes into desired corneal cells to intercept pathologic pathways and processes leading to blindness have been identified. This review provides an overview of corneal diseases, nanovector properties and their applications in drug-delivery and corneal disease management.

Citing Articles

Long-lasting comfort ocular surface drug delivery by in situ formation of an adhesive lubricative Janus nanocoating.

Wang C, Liu X, Lv W, Kuang X, Wu F, Fan X Sci Adv. 2025; 11(10):eads0282.

PMID: 40053587 PMC: 11887845. DOI: 10.1126/sciadv.ads0282.

Adhesion Mechanism, Applications, and Challenges of Ocular Tissue Adhesives.

Hu Z, He X, Teng L, Zeng X, Zhu S, Dong Y Int J Mol Sci. 2025; 26(2).

PMID: 39859199 PMC: 11765468. DOI: 10.3390/ijms26020486.

Corneal strain influences keratocyte proliferation and migration through upregulation of ALDH3A1 expression.

Zhang Q, Zhou X, Zhang W, Wang X, Dou S, Zhao L FASEB J. 2024; 38(23):e70236.

PMID: 39652089 PMC: 11627209. DOI: 10.1096/fj.202401392R.

Advancements in Hydrogels for Corneal Healing and Tissue Engineering.

Wu K, Qian S, Faucher A, Tran S Gels. 2024; 10(10).

PMID: 39451315 PMC: 11507397. DOI: 10.3390/gels10100662.

Potential therapeutic effects of peroxisome proliferator-activated receptors on corneal diseases.

Chow B, Yu Lee I, Liu C, Liu Y Exp Biol Med (Maywood). 2024; 249:10142.

PMID: 38993197 PMC: 11238193. DOI: 10.3389/ebm.2024.10142.

References

Ma X, Bao H, Cui L, Zou J . The graft of autologous adipose-derived stem cells in the corneal stromal after mechanic damage. PLoS One. 2013; 8(10):e76103. PMC: 3787960. DOI: 10.1371/journal.pone.0076103. View

Tadros T, Izquierdo P, Esquena J, Solans C . Formation and stability of nano-emulsions. Adv Colloid Interface Sci. 2004; 108-109:303-18. DOI: 10.1016/j.cis.2003.10.023. View

Kolhe P, Misra E, Kannan R, Kannan S, Lieh-Lai M . Drug complexation, in vitro release and cellular entry of dendrimers and hyperbranched polymers. Int J Pharm. 2003; 259(1-2):143-60. DOI: 10.1016/s0378-5173(03)00225-4. View

Zhou X, Zhang X, Yu X, Zha X, Fu Q, Liu B . The effect of conjugation to gold nanoparticles on the ability of low molecular weight chitosan to transfer DNA vaccine. Biomaterials. 2007; 29(1):111-7. DOI: 10.1016/j.biomaterials.2007.09.007. View

Kinoshita S, Adachi W, Sotozono C, Nishida K, Yokoi N, Quantock A . Characteristics of the human ocular surface epithelium. Prog Retin Eye Res. 2001; 20(5):639-73. DOI: 10.1016/s1350-9462(01)00007-6. View

Hu J, Kovtun A, Tomaszewski A, Singer B, Seitz B, Epple M . A new tool for the transfection of corneal endothelial cells: calcium phosphate nanoparticles. Acta Biomater. 2011; 8(3):1156-63. DOI: 10.1016/j.actbio.2011.09.013. View

Fini M . Keratocyte and fibroblast phenotypes in the repairing cornea. Prog Retin Eye Res. 1999; 18(4):529-51. DOI: 10.1016/s1350-9462(98)00033-0. View

Zarbin M, Montemagno C, Leary J, Ritch R . Nanomedicine in ophthalmology: the new frontier. Am J Ophthalmol. 2010; 150(2):144-162.e2. DOI: 10.1016/j.ajo.2010.03.019. View

Wilson S, Chaurasia S, Medeiros F . Apoptosis in the initiation, modulation and termination of the corneal wound healing response. Exp Eye Res. 2007; 85(3):305-11. PMC: 2039895. DOI: 10.1016/j.exer.2007.06.009. View

10.

Di Tommaso C, Bourges J, Valamanesh F, Trubitsyn G, Torriglia A, Jeanny J . Novel micelle carriers for cyclosporin A topical ocular delivery: in vivo cornea penetration, ocular distribution and efficacy studies. Eur J Pharm Biopharm. 2012; 81(2):257-64. DOI: 10.1016/j.ejpb.2012.02.014. View

11.

Matsui T, Nishino Y, Maeda S, Yamagishi S . PEDF-derived peptide inhibits corneal angiogenesis by suppressing VEGF expression. Microvasc Res. 2012; 84(1):105-8. DOI: 10.1016/j.mvr.2012.02.006. View

12.

Jwala J, Boddu S, Shah S, Sirimulla S, Pal D, Mitra A . Ocular sustained release nanoparticles containing stereoisomeric dipeptide prodrugs of acyclovir. J Ocul Pharmacol Ther. 2011; 27(2):163-72. PMC: 3078652. DOI: 10.1089/jop.2010.0188. View

13.

Davis M, Zuckerman J, Choi C, Seligson D, Tolcher A, Alabi C . Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010; 464(7291):1067-70. PMC: 2855406. DOI: 10.1038/nature08956. View

14.

Cursiefen C . Immune privilege and angiogenic privilege of the cornea. Chem Immunol Allergy. 2007; 92:50-57. DOI: 10.1159/000099253. View

15.

Calvo P, Alonso M . Comparative in vitro evaluation of several colloidal systems, nanoparticles, nanocapsules, and nanoemulsions, as ocular drug carriers. J Pharm Sci. 1996; 85(5):530-6. DOI: 10.1021/js950474+. View

16.

Flanagan J, Willcox M . Role of lactoferrin in the tear film. Biochimie. 2008; 91(1):35-43. DOI: 10.1016/j.biochi.2008.07.007. View

17.

Streilein J . New thoughts on the immunology of corneal transplantation. Eye (Lond). 2003; 17(8):943-8. DOI: 10.1038/sj.eye.6700615. View

18.

Chang J, Gabison E, Kato T, Azar D . Corneal neovascularization. Curr Opin Ophthalmol. 2001; 12(4):242-9. DOI: 10.1097/00055735-200108000-00002. View

19.

Taha E, El-Anazi M, El-Bagory I, Bayomi M . Design of liposomal colloidal systems for ocular delivery of ciprofloxacin. Saudi Pharm J. 2014; 22(3):231-9. PMC: 4099572. DOI: 10.1016/j.jsps.2013.07.003. View

20.

Peer D, Karp J, Hong S, Farokhzad O, Margalit R, Langer R . Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2008; 2(12):751-60. DOI: 10.1038/nnano.2007.387. View